A study in the journal Obesity evaluated the impact of new anti-obesity medications (AOMs) on cardiovascular disease (CVD) among obese individuals, finding that these medications reduce the risk of CVD complications, particularly heart failure and atrial fibrillation.
Researchers discover new spiroindolin-1,2-diazepine derivatives with anti-Alzheimer therapeutic potential
In a recent study, researchers designed substituted spiro indolin-1,2-diazepine derivatives ‘5a–v’ with cholinesterase inhibitory activities as anti-Alzheimer’s disease agents.